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Abstract
Objective: This study explores differences in spending and utilization of health care
services for an older person with frailty before and after a hip fracture.
Data Sources: We used individual-level patient data from five care settings.
Study Design: We compared utilization and spending of an older person aged older
than 65 years for 365 days before and after a hip fracture across 11 countries and
five domains of care as follows: acute hospital care, primary care, outpatient specialty
care, post–acute rehabilitative care, and outpatient drugs. Utilization and spending
were age and sex standardized..
Data Collection/Extraction Methods: The data were compiled by the International
Collaborative on Costs, Outcomes, and Needs in Care (ICCONIC) across 11 countries
as follows: Australia, Canada, England, France, Germany, the Netherlands,
New Zealand, Spain, Sweden, Switzerland, and the United States.
Principal Findings: The sample ranged from 1859 patients in Spain to 42,849 in
France. Mean age ranged from 81.2 in Switzerland to 84.7 in Australia. The majority
of patients across countries were female. Relative to other countries, the United
States had the lowest inpatient length of stay (11.3), but the highest number of days
were spent in post–acute care rehab (100.7) and, on average, had more visits to spe-
cialist providers (6.8 per year) than primary care providers (4.0 per year). Across
almost all sectors, the United States spent more per person than other countries per unit
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($13,622 per hospitalization, $233 per primary care visit, $386 per MD specialist visit).
Patients also had high expenditures in the year prior to the hip fracture, mostly con-
centrated in the inpatient setting.
Conclusion: Across 11 high-income countries, there is substantial variation in health
care spending and utilization for an older person with frailty, both before and after a
hip fracture. The United States is the most expensive country due to high prices and
above average utilization of post–acute rehab care.
K E YWORD S
health systems, hip fracture, international comparisons
What is known on this topic
• Health systems spend different amounts caring for patients.
• Older persons with frailty are more likely to incur high levels of spending as compared to
other older populations.
• International comparisons of health systems mostly focus on the inpatient setting
What this study adds
• This study compares health care utilization and spending across 11 high-income countries for
an older adult with frailty across five domains of care, including acute hospital care, primary
care, outpatient specialty care, post–acute rehabilitative care, and outpatient drugs.
• The United States is the most expensive country due to high prices and above average utili-
zation of post–acute rehab care.
• Across 11 high-income countries, there is substantial variation in health care spending and
utilization for an older person with frailty, both prior to and after a hip fracture.
1 | INTRODUCTION
A key challenge faced by many health systems is how to best design
services to provide care to a small number of high-need high-cost
(HNHC) patients. One important group of HNHC patients is older
adults with frailty. Frail older adults are weak, often have multiple com-
plex medical needs, and often require assistance for daily activities
(such as dressing, eating, toileting, mobility, etc.). Frailty is a strong pre-
dictor of poor clinical outcomes.1–4 In addition, the frail population is
much more likely to incur high levels of spending as compared to other
older populations, including higher levels of potentially modifiable
spending related to avoidable hospitalizations.5–7 As the world popula-
tion ages, and we see trends of increased longevity in older people, the
incidence of frailty is expected to rise. Therefore, it is critical for health
systems to identify ways to optimize care their care. One way to do
this is by examining how care patterns for older patients with frailty
vary across systems and, importantly, understanding how best practices
can be applied from one health system to another.
A reliable marker of frailty among older adults is hip fracture,8
which accounts for the majority of fractures related to fragility glob-
ally.9 By 2050, the annual incidence of hip fracture worldwide is
expected to rise over 6 million.10 Hip fracture is also highly associated
with physical and mental disability, high mortality, and increased costs,
thus requiring considerable health care resources from different parts
of the health system.11–14 As hip fractures almost always require a
hospital admission and usually require surgery, the vast majority will
be recorded in hospital admissions data and can thus serve as a robust
and reliable tracer condition to explore differences in resource use
across health systems.8
As part of the International Collaborative on Costs, Outcomes
and Needs in Care (ICCONIC), we explored cross-national variations
in care trajectories and resource use for frail elders across health
systems in 11 countries, which have different models of health care
provision and reimbursement as follows: Australia, Canada, England,
France, Germany, the Netherlands, New Zealand, Spain, Sweden,
Switzerland, and the United States. We made use of hip fracture in
patients older than age 65 years as a tracer condition for frailty
in order to identify a comparable set of patients across the 11 health
systems. Making use of patient-level datasets linked across multiple
care settings—spanning primary care, specialty services, acute hospital
care, and post–acute care—we explored the variations in utilization
and costs of health services across care settings and health systems in
the 365 days before and after a hip fracture. Our study focuses on
the following three questions: (1) how do patterns of spending and
utilization of care for hip fracture patients differ across care settings
in health systems that are structured and financed differently; (2) how
do patterns of spending and utilization of care for these patients differ
from patterns of spending and utilization in the 365 days prior to the
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hip fracture by country; and finally (3) to what extent do we observe
notable differences in the total amount of spending and utilization of
care for hip fracture patients across health systems?
2 | DATA AND METHODS
Our methodological approach to examine variations in health systems
utilization and spending combines two existing approaches that are
relatively novel for international comparison of health systems. First,
we proposed to use linked patient-level data to examine the entire
care pathway, rather than focusing only on care in the hospital setting.
Second, our unit of analysis is a specific type of HNHC patient, which
we termed a patient persona, whom we followed throughout the sys-
tem to record instances of utilization and associated spending over
the course of a year. This approach builds on the use of clinical
vignette methodologies that have been used by other projects to
examine resource use in the inpatient setting15 and by international
organizations to examine variations in clinical practice.16
2.1 | Data
We use linked patient-level data from 11 countries as follows:
Australia, Canada, England, France, Germany, the Netherlands,
New Zealand, Spain, Sweden, Switzerland, and the United States,
accessed by members of the ICCONIC collaborative. Datasets
included linked data across different domains of care, including pri-
mary care, outpatient specialty care, acute hospital care, post–acute
rehabilitative care, outpatient pharmaceuticals, home health care, and
long-term care. Specific details of each dataset used can be found in
Table 1 of Appendix S1. Countries ability to collect comprehensive
data across each domain for health care utilization and spending cate-
gories varied (Table 2 of Appendix S1).
The representativeness of the population for each dataset is
found in Table 2 of Appendix S1. Data in three countries—New
Zealand, Sweden, and Switzerland—covered their entire population.
Data in three other countries were from specific regions—Australia
(New South Wales), Canada (Ontario), and Spain (Aragon). Data in the
remaining five countries were large, regionally diverse samples, includ-
ing in England, France, Germany, the Netherlands, and the United
States. The proportion of patients covered in each dataset varied
across countries, from 3% in Spain (Aragon) and 7% in England to
100% in New Zealand, Sweden, and Switzerland. Data from most
countries were from 2016 to 2017, except for Spain, Sweden, and
Switzerland, which is from 2015 to 2016. Australia (2012–2016)
and England (2014–2017) used data for a longer time period to allow
for more observations given the size of the sample.
2.2 | Sample selection
Using the framework from the National Academy of Medicine report
“Effective Care for High-Need Patients” as a starting point, we selected
a patient persona that is representative of a frail older person. A frail
older person was one of five priority populations identified as being
among the most expensive to care for, have substantial health care
needs, and are particularly vulnerable to poor-quality care.17 The other
priority populations were a person with a progressing, advanced illness;
a person with complex multimorbidity; a young person with a major dis-
ability; and children with complex needs.
Our starting point was to define comparable group of patients to
make up the hip persona for identification. We focused on patients
older than 65 years across all systems, who were admitted to hospital
with a primary diagnosis of hip fracture, which can be identified using
the International Classification of Diseases–10th revision (ICD-10)
diagnostic codes, as defined by the World Health Organization: S72.0,
S72.1, and S72.2. These three diagnostic codes all represent fractures
in the upper part of the femur, although each code represents a differ-
ent type of fracture, which may require different procedures to treat.
As our group of analysis, we focus on the patients with this diagnosis
who received one of three procedures: total hip replacement, partial
hip replacement, or osteosynthesis (or pinning), which we identified
with the relevant procedure codes in each country. The data from
Spain and the Netherlands were not coded using ICD-10 codes. Spain
relied on ICD-9 codes, and the Netherlands used comparable diagnos-
tic codes available in the insurer data used for this study with help
from clinical experts in the country. To advise on the selection of
national codes and final group for analysis, we consulted with an
international advisory board composed of national and international
advisors from clinical, health policy, and research backgrounds
(Table 3 of Appendix S1).
Across countries, we tracked spending and utilization across five
domains of care as follows: (1) acute hospital care, (2) post–acute
rehabilitative care, (3) primary care, (4) outpatient/ambulatory spe-
cialty care, and (5) outpatient pharmaceuticals. For an outline of
spending and utilization categories, please see Figures 1 and 2 of
Appendix S1. To identify and follow the hip fracture persona across
their pathway of care over a period of a year and establish the excess
utilization and spending associated with the hip fracture, we required
3 years of patient-level data. One year of data were used to identify
all relevant hip fracture patients using the characteristics outlined
above. The follow-up year was used to measure the service use and
spending incurred by each patient, across all care settings, from day
1 of hospitalization for the 365 days that follow. A look-back year
was used to establish a look-back period of 365 days for comparison
and to establish baseline utilization and spending prior to hip fracture
(Figure 3 of Appendix S1). We used the look-back year a “baseline”
year across all patients and countries. Given that all spending data is
age- and sex-adjusted, we inferred that any additional dollar of spend-
ing observed in the year following the index hospitalization compared
to the look-back year is largely attributable to the hip fracture event
per se and related complications.
2.3 | Analysis
Due to constraints in data sharing, each country was only able to pro-
vide aggregated data for comparison. For each of the utilization and
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spending categories, countries supplied aggregated data reflecting
mean use and spending in seven age groups (65–69, 70–74, 75–79,
80–84, 85–89, 90–94, and 95 years and up) stratified by sex.
While all countries provided expenditure data, it is important to note
that we used the perspective of the health care payer across all coun-
tries. In most countries, this is carried out either directly by an insurance
or sickness fund (Germany and the Netherlands) or directly from a
national form of health insurance (the United States with Medicare pro-
gram, Canada, etc.). Therefore, our study does not capture full costs (as it
does not account for the fixed costs of all structures within a health sys-
tem). It only captures the prices actually paid for the services, which
across all countries, already included the fixed costs of the system. In
addition, cost accounting methods used to estimate expenditure differ
across countries, in part due to the differences in existing payment sys-
tems (Table 4 of Appendix S1). For example, some countries are able to
report direct spending from incurred costs (those that rely on FFS
entirely), while others provide information on reimbursement for specific
episodes (e.g., diagnosis-related group [DRG]) or an unweighted average
unit prices. There are also differences in payment systems within coun-
tries across the different sectors. For example, pharmaceutical spending
across countries reflects the amount of pharmaceutical spending in the
outpatient setting and includes different amounts of out-of-pocket con-
tributions. In the United States, this expenditure category captures Part
D spending; in Australia and Sweden, these estimates include co-pay-
ments. Finally, the reporting and imputation of capital investments or
indirect costs also vary across system.
In order to reliably compare spending, we first applied the Organiza-
tion for Economic Co-operation and Development's (OECD) Actual Indi-
vidual Consumption Purchasing Power Parities (AIC PPPs) to the
expenditure data. AIC PPPs, rather than GDP PPPs, are currently used by
the OECD as the most reliable economy-wide conversion rates for health
expenditure. Across each country, we applied 2017 AIC PPPs to all expen-
ditures by age groups across the seven age groups, stratified by sex.
We then performed an age and sex direct standardization using
the US sample population as the reference population for all coun-
tries. For each age group and sex, all utilization and spending mea-
sures were weighted and recalculated against the US sample
population weights. The totals are then calculated by weighting each
individual group and sex's shares on the original country-specific total
to generate total, male, and female age–sex standardized values.
Across each category of spending and utilization, we then compared
age–sex standardized results.
The institutional review board at the Harvard T.H. Chan School of
Public Health approved this study.
3 | RESULTS
3.1 | Sample characteristics
Across the 11 countries, we identified a number of patients hospital-
ized with hip fracture undergoing one of the three procedures as fol-
lows (total replacement, partial replacement, or osteosynthesis): 2511
patients in Australia (New South Wales); 9872 patients in Canada
(Ontario); 2738 patients in England; 42,849 patients in France; 13,998
patients in Germany; 4463 patients in the Netherlands; 2940 patients
in New Zealand; 1859 patients in Spain (Aragon); 14,764 patients in
Sweden; 6860 patients in Switzerland; and 29,134 patients in the
United States (Table 1). The mean patient age ranged from 81.2 years
(standard deviation [SD] 6.9) in Switzerland to 85.4 years (SD 7.0) in
Spain. The sample was predominantly female, with the proportion of
women as high as 77.1% in France and the lowest at 62.8% in
Australia. Countries varied in the ability to capture secondary diagno-
ses in the index hospitalization, ranging from an average of 3.7 com-
orbidities in the United States to 1.1 in New Zealand and Canada.18,19
In all countries but Spain, the most common diagnostic code was
S72.0: ranging from 68.1% of the sample in England to 42.4% of the
sample in Spain. The majority of patients with a hip fracture
(all diagnosis) underwent osteosynthesis (pinning); for all countries
apart from England, this amounted to 46.6% of the sample. Sweden
had the most pinning of all countries, where 63.9% of the sample
underwent this procedure. Total replacement was the least common
procedure, performed on up to 15.6% of the sample in Switzerland
and on as few as 3.0% of patients in Spain (Table 1).
3.2 | Utilization differences across countries
The differences in utilization across the countries for key care settings
are illustrated in Figure 1. Most patients across countries had around
two hospitalizations over the 365-day study period, including the
index hospitalization (Figure 1A). Germany and England had the lon-
gest length of stay, at 29.5 and 29.3 days, respectively, nearly three
times the average length of stay in the United States (11.3) and the
Netherlands (11.7) (Figure 1B). Of the countries that had data on
the facility-based rehabilitative care sector, Sweden (9.7) had the
fewest number of days spent in this sector, while the United States
(46.4) had the highest number (Figure 1C). When combined, France
and the United States had the highest number of days in hospitals and
rehab facilities over the year, summing to a total of with 54.2 days per
person in France and 57.6 days per person in the United States.
Of the four countries that had data on utilization of home- and
community-based rehab care, the United States also had the most
(54.3 days), again followed by France (32.4 days). Canada and the
Netherlands had far less at 5 days and 16.5 days, respectively
(Figure 1D). Of the total days spent in hospital and institutional rehab,
for most countries, the majority was concentrated in the index admis-
sion, with the exception of the United States (Figure 1E).
The number of unique visits to primary care providers and outpa-
tient specialists varied considerably across countries (Figure 1F,G).
On average, the United States had the fewest number of visits to pri-
mary care providers (4.0) over the course of the year, while Germany
(17.3) had the most. When combined, Germany and Spain had the
highest number of visits across both specialists and primary care
providers. The United States was the only country to have more MD
specialist visits than primary care doctor visits.
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France had the greatest number of unique drugs prescribed at
14.3 drugs per person. While Australia had the fewest unique drugs
prescribed (8.3 drugs per person) (Figure 1H). The United States was
an average utilizer with 10.6 drugs per person.
3.3 | Spending differences across countries
The differences in spending across different care settings are illustrated
in Figure 2, while Figure 3 shows differences in spending taking into
account differences in utilization. There was a large difference in total
spending for acute hospital care, ranging from $28,398 per person in
Australia to $11,981 in the Netherlands (Figure 2). The index hospitali-
zation accounted for the majority of the spending in this category for
most countries (see Figure 2A). When accounting for the number of
hospitalizations over the year, the United States had the most spending
per hospitalization ($13,622), closely followed by Switzerland ($13,177),
and England had the lowest cost per hospitalization ($7305) (Figure 3A).
Of the countries that were able to measure facility-based rehabili-
tation spending, the United States spent the most per patient over
the course of the year ($25,216), nearly double than the next highest
spender Canada ($12,701) (Figure 2B). There was a similar pattern for
total expenditure of home- and community-based rehab spending,
where the United States spent $4176 per patient per year, compared
to $869 in France (the next highest spender) and $432 in Canada (the
lowest spender) (Figure 2C). While the United States had the greatest
number of institutional and home- and community-based rehabilita-
tion days, they also had the most expensive institutional rehab per
day ($544) when compared to others, followed closely by Canada
($505 per rehabilitation day) (Figure 3B). Canada had the most expen-
sive home- and community-based rehabilitation day ($86 per day)
followed by the United States ($77) (Figure 3C).
There were differences across the countries in spending related
to primary care services, with Spain, Canada, Sweden, and the United
States all spending around $900 per year and Australia, England, and
France all spending closer to $350 per year (Figure 2D). Most of the
difference in total seems to be accounted for by the number of visits,
with most countries spending between $32 and $70 per visit. The
exception is the United States and Sweden who spent $233 and $137
per visit, respectively (Figure 3D).
There was little variation across countries related to total outpa-
tient specialty care spending over the year with most countries spend-
ing around $800 per person, apart from the United States that spent
$3658 per person (Figure 2E). However, the cost per MD specialist
visit was more varied, with the United States spending comparatively
more (Figure 3E). Outpatient drug spending was the highest in the
F IGURE 1 Utilization across key care settings over 365 days. Note: *Primary care visits for Sweden represent average yearly consumption for
this cohort rather than linked patient-level data
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United States ($3127 per person) and the lowest in England ($484 per
person) (Figure 2F). When adjusting for drug utilization, England had
the lowest cost per drug prescribed ($41) followed by New Zealand
($53); the United States had the highest cost per drug ($297)
(Figure 3F).
3.4 | Comparison to the look-back year
Using the expenditure in the 365 days prior to the hip fracture as
baseline expenditure for this persona, we examined the relative
increase in expenditure for each care category in the period
365 days following the expenditure. All countries saw a large
increases in the general acute care spending in the year following
the hip fracture relative to the 365 days before. This was most pro-
nounced in the countries that had the lowest baseline expenditure
such as New Zealand, where expenditure for this care setting
increased by 879% (from $1541), as compared to 253% in Sweden
(from $4972) and 437% in the United States (from $5868) (Figure 4,
Appendix 5). Of the countries that were able to collect rehab data,
whether facility based or in the home/community, all countries saw
an increase in spending relative to the look-back year. The greatest
F IGURE 2 Spending across key care
settings over 365 days (USD). Note: All
figures are shown in Intl. USD. For acute
hospital spending, index spending is part
of the total non-index spending. For
France and Spain, the breakdown for
index spending is not available; therefore,
only the total spending is shown (for both
index and nonindex)
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F IGURE 3 Utilization adjusted spending across key care settings over 365 days. Note: All figures are shown in Intl. USD. Panel A: General
acute hospital spending/total hospitalizations. Panel B: Facility-based rehab spending/total days in rehab facilities. Panel C: Home- or community-
based rehab spending/number of days in home- or community-based rehab. Panel D: Total primary care spending/total visits to the primary care
provider. Panel E: MD outpatient specialty spending/number of visits to the MD specialist. Panel E: Total outpatient pharmaceutical spending/
number of unique drugs prescribed
F IGURE 4 Percent change in expenditure (look-back year compared with current year). Note: Percentage values are calculated as (current
year expenditure – look-back year expenditure)/(look-back year expenditure) for each care setting [Color figure can be viewed at
wileyonlinelibrary.com]
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increase in facility-based rehab was in Germany, who had very low
baseline spending. The United States saw a large increase in rehab
spending (437%) despite having already high baseline spending in
this care setting, averaging at $4693 per patient. The Netherlands
and the United States saw the greatest increase in home- and
community-based rehab (370% and 278%, respectively), although
the United States was spending nearly four times as much in the
baseline year ($3864 per patient compared to $1123 per patient)
(Figure 5 of Appendix S1).
Spending in the other three categories (primary care, outpatient
specialty, and outpatient drugs) did not uniformly increase across
countries, with many experiencing a decline in the expenditures asso-
ciated with these care settings instead. In the study year, England,
France, the Netherlands, and the United States, all saw small
decreases in relative expenditures across all three of these categories
as compared to the look-back year. Canada (68%) and Germany (2%)
saw increases in primary care spending of different degrees, while
Australia (48%) and Spain (59%) saw increases in relative outpatient
specialty expenditure.
4 | DISCUSSION
In this study, we examined patterns of utilization and spending for an
older frail adult recovering from a hip fracture across 11 countries as
follows: Australia, Canada, England, France, Germany, the Netherlands,
New Zealand, Spain, Sweden, Switzerland, and the United States. The
resources used by this HNHC persona vary considerably across coun-
tries, although the United States stands out as the highest spender in
every care setting. Across all countries, considerable resource use is
devoted to inpatient care and rehabilitative care, both in facilities and in
the community. We found that this group of patients also have high
expenditures in the year prior to the hip fracture, mostly concentrated
in the inpatient setting and also make greater use of primary care and
outpatient specialty care relative to the general population as measured
by the OECD.20 This is likely related to underlying frailty but also varies
across countries, suggesting that differences in how health services are
organized and provided may also play a role. Our study demonstrates
the importance of looking across the system to understand the true
resource use of complex patients, which is essential if policy makers
want to identify areas for improvements in care.
Our results have important implications for policy makers inter-
ested in better understanding the relative performance of their coun-
try with regards to care for this population. For example, our findings
suggest that the United States appears to be the least efficient in car-
ing for this persona, in both price and quantity. Across all sectors, the
United States spends more per unit of health care use in addition to
having more and longer durations of time spent in facility-based rehab
and home rehab than other countries. In addition, when we sum days
spent in acute and post–acute care settings over the course of the
year, the United States becomes the highest utilizer of care overall.
These patterns may be culminating a number of different issues in the
care pathway. It is possible that patients are discharged “quicker but
sicker” from the hospital in the United States because of the widely
accessible post–acute care infrastructure covered by Medicare.21,22
Other countries, like England, do not have a comprehensive provision
of accessible post–acute care service and, instead, observe much lon-
ger hospital length of stay.23 Another possibility is that US patients
have less access to affordable long-term care, as it is not covered by
the Medicare program.24 This may lead to a substitution of care,
where long-term care services are being provided in the post–acute
setting (predominately skilled nursing facilities).
Among the countries able to provide information on post–
acute rehab utilization and costs, we observed that those with
universal long-term care systems (such as Canada, the Netherlands,
and Sweden) spend fewer days and subsequent lower costs in the
post–acute rehab setting. This again suggests that in countries
without easily affordable and accessible long-term care, care and
costs are being shifted into the post–acute setting. In the case of
England, which has neither comprehensive long-term care nor
post–acute care coverage, we observed that the hospital setting
bears a bigger burden relative to other countries in terms of longer
length of stay. Our findings have important implications for those
concerned with allocative efficiency of health care spending.
Particularly for this patient group, the setting where care happens
can have substantial repercussions on total spending. Countries
like the Netherlands and Sweden are structured to utilize more
long-term care than other costly alternatives.
Another key objective of this work was to quantify the
resource use of a frail older patient and how it changes when they
suffer an acute event. The look-back year reveals to us that, even
prior to the hip fracture, frail older patients have high levels of
health care utilization and costs. An acute event such as hip frac-
ture causes costs in these settings to balloon, largely driven by
increases in inpatient and rehabilitative care. Interestingly, many
countries see expenditures fall across the primary care and outpa-
tient specialty settings likely because they are institutionalized or
become deceased.
Our work also sheds light on other factors that may contribute to
the higher US expenditure for this persona. In the outpatient setting,
we found important differences in the relative distribution of primary
care and specialty care services. The United States is the only country
that utilizes more speciality care visits than primary care, both in the
year before and after the hip fracture. Despite being an average uti-
lizer of unique drugs per person, the United States spends substan-
tially more. On the other hand, England and New Zealand stand out as
the lowest per unit spenders, which may be explained by well-
documented differences in the various economic and regulatory
instruments used. For example, in England, the National Institute of
Health and Care Excellence regulates the use and price of new drugs.
New Zealand is one of the few countries that have an effective
tendering system for pharmaceuticals, which may contribute to lower
prices.25,26
This work makes important contributions to the literature on
international comparisons. While several European projects have
demonstrated the differences that exist across European health
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systems in the intensity of care delivered,27 the basket of services
delivered,15 treatment pathways,28 outcomes,29 and costs15,28,30 for
patients with similar diagnoses, most have focused on comparisons of
the inpatient setting. To our knowledge, only one other project,
EuroHOPE, has compared patient trajectories over time, although for
a different subset of countries, patients, and years. Our study builds
upon this work by looking specifically at HNHC patients and consider-
ing chronic disease, rather than only acute, care using contemporary
data. Survey work in these countries has also demonstrated differ-
ences in the coordination of care for HNHC patients, highlighting
particular challenges for primary care providers specifically.31
Our work has some key limitations. First, though we have done
our best to ensure data comparability across countries, there are some
differences in the types of data used as well as in the representative-
ness and completeness of data across countries, which may influence
the comparability of estimates across certain categories. In the United
States specifically, our sample of data represents patients covered by
the Medicare fee-for-service system, which may incur different
spending to those covered through Medicare advantage. Second,
there are differences in national coding practices and cost accounting
practices of the data across countries that in turn may influence the
results, for example, countries with fee-for-service systems will have
more precise estimates of expenditure than those with global budgets
where costs have been estimated using a top-down approach. We
have tried to document these as much as possible so as to identify
potential sources of bias. In addition, the expenditure estimates
reported only reflect the costs incurred by the payer and, for the most
part, do not capture any additional out-of-pocket payments, which
are likely to vary across countries and care settings. The notable
exception to this is for outpatient pharmaceutical payments where
some countries do capture co-pays, such as Australia and Sweden.
We reported differences in coverage across countries alongside our
results, so that readers can better understand where these types of
payments are likely to exist by country. Third, while all results are age
and sex adjusted, we do not adjust for comorbidities, which may influ-
ence expenditure and utilization. For example, the United States has
higher comorbidities than most of the other countries, which may
contribute to higher spending. Finally, while we aimed to compare the
entire care pathway across countries, most countries are missing some
utilization or expenditure data from key care settings particularly
around post-acute and long-term care. This limits the extent we are
able to compare total spending and utilization or better understand
patterns of substitution between care settings. However, we believe
that the linked data we have currently collected are among the most
comprehensive data reflecting the care pathway across countries.
5 | CONCLUSIONS
Most cross-country comparisons to date have focused on looking at
variations in the utilization and cost of hospital care.27–29 Our results
illustrate that across health systems, there is considerable variability
with regards to the relative share of care, and expenditures, that
occurs in hospitals for this patient group. Limiting comparisons to only
the inpatient setting likely provides a misleading picture of resource
use for these patients. Until we have a broader perspective of the dis-
tribution of resources across the care pathway, health policy will
remain fragmented and miss out on the biggest opportunities to
improve care for this group of patients and improve the efficiency of
health care systems.
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